Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Paul, Mical ^a   Dickstein, Yaakov ^b   Borok, Sara ^c   Vidal, Liat ^c   Leibovici, Leonard ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Rambam Health Care Center   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ADVERSE OUTCOME; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; GRAM POSITIVE BACTERIUM; HUMAN; LENGTH OF STAY; MALIGNANT NEOPLASM; MORTALITY RATE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SYSTEMATIC REVIEW; GRAM POSITIVE INFECTION; META ANALYSIS; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; FEBRILE NEUTROPENIA; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84903754530     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003914.pub3     Document Type: Review

References (76)

1. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, et al.Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clinical Infectious Diseases 2003;37(3):382-9.
2. Cometta A, Kern WV, Debock R, Paesmans M, Vandenbergh M, Crokaert F, et al.An EORTC-IATG double-blind trial of vancomycin (Van) versus placebo (Pla) for persistent fever in neutropenic cancer patients (NCP) given piperacillin/tazobactam (PT) monotherapy. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001:445.
3. Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F, et al.Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clinical Microbiology and Infection 2006;12:212-6.
4. Wade JC, Glasmacher A. Vancomycin does not benefit persistently febrile neutropenic people with cancer. Cancer Treatment Reviews 2004;30(1):119-26.
5. Del Favero A, Menichetti F, Guerciolini R, Bucaneve G, Baldelli F, Aversa F, et al.Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrobial Agents and Chemotherapy 1987;31(7):1126-9.
6. de Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, et al.A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrobial Agents and Chemotherapy 1985;28(6):824-8.
7. EORTC-1991. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Journal of Infectious Diseases 1991;163(5):951-8.
8. Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. Journal of Antimicrobial Chemotherapy 2000;45(6):843-9.
9. Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, et al.Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. American Journal of Medicine 1986;81(2):237-42.
10. Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. American Journal of Medical Sciences 1984;287(1):16-23.
11. Marie JP, Pico J, Lapierre V, Maulard C, Pappo M, Chiche D, et al.Empirical treatment of febrile episodes in cancer patients with prolonged neutropenia: comparative study of ceftazidime alone, ceftazidime+amikacin, and ceftazidime+vancomycin [Traitement empirique des episodes febriles survenant chez les patients cancereux presentant une neutropenie prolongee: essai comparatif ceftazidime seule, ceftazidime+amikacine et ceftazidime+vancomycine]. Medicine et Maladies Infectieuses (Medicine and Infectious Diseases) 1991;21:386-8.
12. Marie JP, Pico JL, Chiche D, Fitoussi F, Delmer A, Baume D, et al.Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients. Presse Medicale (Medical Press) 1988;17(37):1968-70.
13. Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1998;41 Suppl D:57-64.
14. Pico JL, Marie JP, Chiche D, Guiguet M, Andremont A, Lapierre V, et al.Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. European Journal of Medicine 1993;2(5):275-80.
15. Menichetti F, Del Favero A, Guerciolini R, Tonato M, Aversa F, Roila F, et al.Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole. Infection 1986;14(6):261-7.
16. Molina F, Pedro L, Rosell R, Barnadas A, Font A, Maurel J, et al.Randomized open and prospective study of two antibiotic schedules (with and without teicoplanin) for post-chemotherapy episodes of neutropenic fever. Oncologia: IV Congresso Nacional de la SEOM. 1993; Vol. 16:247.
17. De Pauw BE, Novakova IR, Donnelly JP. Options and limitations of teicoplanin in febrile granulocytopenic patients. British Journal of Haematology 1990;76(Suppl 2):1-5.
18. Novakova I, Donnelly JP, De Pauw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy 1991;35(4):672-8.
19. Novakova I, Donnelly JP, Muytjens HL, De Pauw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. 28th Interscience Conference Antimicrobials Agents and Chemotherapy. American Society of Microbiology, 1988:16.
20. Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, et al.Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrobial Agents and Chemotherapy 1992;36(5):1062-7.
21. Verhagen CS, de Pauw B, de Witte T, Janssen J, Williams K, de Mulder P, et al.Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrobial Agents and Chemotherapy 1987;31(2):191-6.
22. Berger C, Kindli K, Niggli D, Nadal D. Meropenem therapy in febrile neutropenic children with cancer seldom affords addition of a glycopeptide. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 2002:251.
23. De Pauw BE, Raemaekers JMM, Schattenberg T, Donnelly JP. Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. Journal of Internal Medicine. Supplement 1997;242(740):69-77.
24. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. European Journal of Cancer 1996;32A(8):1332-9.
25. Elting LS, Rubenstein EB, Rolston KV, Manzullo E, Bodey GP. Impact of vancomycin (vanc) use on duration of fever and mortality in neutropenic patients with gram positive bacteremia (GPB). Proceedings of the Annual Meeting of the American Society of Clinial Oncology. 1996.
26. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clinical Infectious Diseases 1997;25:247-59.
27. EORTC-1983. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology 1983;1(10):597-603.
28. Fauser AA, Lang E, Dolken G, Bross KJ, Schmid J, Sorgel F. Treatment of severe sepsis in bone marrow transplant recipients with teicoplanin in combination with beta-lactams and aminoglycosides. Infection 1991;19:195-200.
29. Granowetter L, Wells H, Lange BJ. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient. Pediatric Infectious Diseases Journal 1988;7:165-70.
30. Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. American Journal of Medicine 1986;81:243-8.
31. Kramer BS, Ramphal R, Rand KH. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrobial Agents and Chemotherapy 1986;30(1):64-8.
32. Libanore M, Bicocchi R, Pantaleoni M, Montanari P, Singhinolfi L, Ghinelli F. Teicoplanin in the therapy of Gram-positive infections in immunocomprised patients [La Teicoplanina nella Terapia di Infezioni da Gram-positivi nell'ospite immunocompomesso]. Giornale Italiano di Chemioterapia (Italian Journal of Chemotherapy) 1991;38:167-9.
33. Lim S, Smith MP, Goldstone AH, Machin SJ. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. British Journal of Haematology 1990;76 Suppl 2:41-4.
34. Link H, Maschmeyer G, Meyer P, Hiddenmann W, Stille W, Helmerking M, et al.Interventional antimicrobial therapy in febrile neutropenic patients. Annals of Hematology 1994;69:231-43.
35. Maschmeyer G, Link H, Hiddenmann W, Meyer P, Helmerking M, Adam D. Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Erlich Society for Chemotherapy. Onkologie (Oncology) 1990;13:38-42.
36. Liu AJ, Chen SL. Analyze the curative effect of norvancomycin using at 44 patients with agranulocyte after chemotherapy. Contemporary Medicine 2000;6(5):63-4.
37. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, Mandelli F. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clinical Infectious Diseases 1992;15(2):290-4.
38. Micozzi A, Venditti M, Amadori S, Pulsoni A, Tirindelli C, Martino P. Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients. British Journal of Haematology 1990;76 Suppl 2:19-23.
39. Moroni C, Viscoli C, Boni L, Garaventa A, Dini G, Haupt R, et al.A randomized study of the empirical antibiotic therapy of the infections in neutropenic patients, affected by neoplastic diseases in paediatric age and under a fever attack. Giornale di Malattie Infettive e Parassitarie (Journal of Infectious and Parasitic Dieases) 1987;39:1194-8.
40. Novakova IR, Donnelly JP, Verhagen CS, De Pauw BE. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. Journal of Antimicrobial Chemotherapy 1990;25(6):985-93.
41. Pizzo AP, Robichaud KJ, Fred AG, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American Journal of Medicine 1982;72:101-11.
42. Pizzo P, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al.A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. The New England Journal of Medicine 1986;315:552-8.
43. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Annals of Internal Medicine 1988;108(1):30-5.
44. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al.Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. The New England Journal of Medicine 2005;353:977-87.
45. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Morbidity and Mortality Weekly Report 1995;44(RR-12):1-13.
46. Cometta A, Marchetti O, Calandra T. Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. European Journal of Cancer 2007;5 Suppl:23-31.
47. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. The Journal of Infectious Diseases 1990;161(3):397-401.
48. Consort statement. http://www.consort-statement.org/.
49. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al.A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases 2001;33(8):1295-301.
50. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al.Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases 2001;32 Suppl 2:114-32.
51. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
52. Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. The Journal of Infectious Diseases 1978;137(1):14-29.
53. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy 1986;29(2):263-70.
54. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The New England Journal of Medicine 1987;317(27):1692-8.
55. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Annals of Internal Medicine 1993;119(7 Pt 1):584-93.
56. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al.Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrobial Agents and Chemotherapy 1995;39(2):445-52.
57. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al.Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrobial Agents and Chemotherapy 1996;40(5):1108-15.
58. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al.Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases 2011;52(5):e56-93.
59. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine 2005;142:979-95.
60. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. The Journal of Antimicrobial Chemotherapy 1993;32(2):325-34.
61. Gurwith M, Brunton JL, Lank B, Ronald AR, Harding GK, McCullough DW. Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. The American Journal of Medicine 1978;64(1):127-32.
62. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester, UK: John Wiley & Sons, Ltd.
63. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al.From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. The Journal of Infectious Diseases 1990;161(3):381-96.
64. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. European Journal of Clinical Microbiology and Infectious Diseases 2013;32(7):841-50.
65. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, et al.Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrobial Agents and Chemotherapy 1994;38(6):1363-7.
66. Pagano L, Antinori A, Ammassari A, Mele L, Nosari A, Melillo L, et al.Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. European Journal of Haematology 1999;63(2):77-85.
67. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
68. Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, et al.German Society of Hematology and Oncology. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Annals of Oncology 2011;22(5):1019-29.
69. Pizzo A. Infection in cancer patients. In: Devita VT, Hellman, S, Rosenberg, SA editor(s). Principles and Practice of Oncology. Philadelphia J.B: Lippincott Williams and Wilkins, 2001.
70. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984;63(4):189-200.
71. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
72. Sievert DM, Boulton ML, Stoltman G, Jonhnson D, Stobierski MG, Downes FP, et al.Staphylococcus aureus resistant to vancomycin -United States, 2002. Morbidity and Mortality Weekly Report 2002;51(26):565-7.
73. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerging Infectious Diseases 2001;7(2):327-32.
74. Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, et al.Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Reviews of Infectious Diseases 1991;13(3):397-404.
75. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003914.pub2]
76. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 2005;55(4):436-44.